Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of “Buy” from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus rating of “Buy” by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $51.40.

A number of research firms recently commented on DYN. Morgan Stanley increased their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Piper Sandler reiterated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Stifel Nicolaus upped their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday. Finally, StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th.

Dyne Therapeutics Trading Down 11.2 %

Shares of DYN opened at $30.31 on Friday. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of -8.51 and a beta of 1.10. The firm’s fifty day simple moving average is $32.58 and its 200-day simple moving average is $35.08. Dyne Therapeutics has a twelve month low of $9.76 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, analysts predict that Dyne Therapeutics will post -2.99 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the transaction, the chief operating officer now directly owns 131,636 shares in the company, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. This represents a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 158,975 shares of company stock worth $5,693,789 over the last ninety days. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its stake in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics in the third quarter valued at $34,000. US Bancorp DE boosted its stake in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares during the last quarter. Values First Advisors Inc. purchased a new stake in Dyne Therapeutics during the 3rd quarter worth about $62,000. Finally, KBC Group NV raised its stake in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.